Scott Rocklage became a Managing Partner of 5AM Ventures in 2004. 5AM Ventures is a capital firm that is looking for companies that are discovering breakthrough medicine and technology to help solve some of the healthcare crises’ that plague the world. The importance of this company required them to have a team of people who hold a great amount of experience in finance, law, business, business operations, medicine and science. It just so happens the Dr. Rocklage has just that, decades of experience in both science and medicine making him an expert in the industry.
Dr. Rocklage’s decades of experience includes being chairman and CEO of Cubist Pharmaceuticals and President and CEO of Nycomed Salutar. Further giving him experience, Dr. Rocklage was the Board of Chairman for Relypsa and Novira; both of these companies have been acquired buy other companies. He also was the Executive Chairman of Ilypsa, Miikana and Semprus. Dr. Rocklage stays an active participant in the healthcare industry as he currently serves as the Board Chairman of Rennovia, Kinestral, and Cidara; he is also a Board member of Epirus and Pulmatrix.
Scott Rocklage had the opportunity to be on the leadership team that led the FDA to approve three new (Omniscan, Teslascan, and Cubicin) U.S New Drug Applications. Dr. Rocklage has invented or co-invented over 30 U.S. patents. Adding to his list of accolades, Dr. Rocklage has over 100 peer-reviewed journal publications and learn more about Scott.
Dr. Scott Rocklage received a Bachelors degree in chemistry from the University of California, Berkley; he also earned a Ph.D, also in Chemistry, from MIT. At MIT he had the privilege of conducting research with the 2005 Chemistry Nobel Prize winner Richard R. Schrock. He currently lives in Massachusetts where he works at 5AM Ventures Waltham location, they also have a location in San Francisco, California and Scott’s lacrosse camp.
More visit: https://about.me/scottrocklage